Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bromocriptine and Insulin Sensitivity (BIS)
NCT02428946Completed
- Sponsor
- University of Amsterdam
- Start
- Oct 2014
- Primary completion
- Nov 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial of bromocriptine in type 2 diabetes mellitus (T2DM), sponsored by University of Amsterdam. Primary endpoint: Timing of administration of bromocriptine at 6 weeks. Started Oct 2014; status: completed.
02
Drugs
bromocriptine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02428946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02428946.